医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MaxiNovel Disclosed the Study Results of Orally Active PD-1/PD-L1 Inhibitors at 2018 AACR

2018年04月18日 AM03:39
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

MaxiNovel Pharmaceuticals, Inc. presented for the first time the preclinical results of its orally active PD-1/PD-L1 inhibitors either as a single agent or in combo studies. The key findings are as follow:

  • As a single agent in a MC38 model, the MaxiNovel compound (120 mpk) showed similar TGI and ratio of CD8+/Treg to that of aPD-1 Ab (200 μg) reported by BMS group (PLoS One. 2016 Nov 18;11(11): e0167251)
  • In the combination study in a MC38 model, the MaxiNovel compound (30 mpk) demonstrated statistically significant combo efficacy with Celebrex, Cisplatin, Epacadostat and aCTLA-4 Ab.
  • In the combination study in a 4T1 model, the MaxiNovel compound (30 mpk) in combination with aCTLA-4 Ab had similar survival ratio as that of aPD-1Ab/aCTLA-4 Ab combination reported by researchers from Australia and US (Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9)

“While IO combination is the industrial trend, the ultimate success will be dependent on the safety of various combinations,” commented Dr. David Moore, MaxiNovel’s SVP of DMPK and Drug Safety. “These orally active small molecule PD-1/PD-L1 inhibitors will provide more flexibility for dose and safety adjustment in the combination with various drugs. Maxinovel has demonstrated statistically significant efficacy of two-component combination with excellent safety in various tumor models. Future goals will be to conduct three, four or even more component combinations, perhaps in a single oral pill.”

Dr. Zujun Li, the Clinical Associate Professor of Medicine at New York University and the PI for immunotherapy clinical trials echoed “we are encouraged by the study results and excited about the small molecules targeting PD-1/PD-L1 pathway. We are looking forward to the orally active drugs to be added to today’s antibody only therapy.”

About MaxiNovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180417006491/en/

CONTACT

MaxiNovel Pharmaceuticals, Inc.
Ms. Pingjing Zhang
pjzhang@maxinovel.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program
  • 新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用
  • 宝洁公司收购德国达姆施塔特默克集团的消费者健康业务
  • MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
  • Vaxart Announces $5 Million Inavir® Revenue Milestone